Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GZR18 is a glucagon-like peptide-1 receptor agonist (GLP-1RA) with potential to treat patients with type 2 diabetes.The primary objective of this Phase 1 study is to investigate safety and tolerability of GZR18 in healthy volunteers.
Lead Product(s): Glucagon-like Peptide-1 Analogue
Therapeutic Area: Endocrinology Product Name: GZR18
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
The new data pertained to three proposed biosimilar Gan & Lee insulin analogs, insulin aspart (GL-ASP), insulin lispro (GL-LIS), and insulin glargine (GL-GLA), and were presented by the primary investigators from Profil, (Germany).
Lead Product(s): Insulin aspart
Therapeutic Area: Endocrinology Product Name: GL-ASP
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2021
Details:
GLR2007 is a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor that Gan & Lee is developing for the treatment of advanced solid tumors including glioblastoma, an aggressive form of brain cancer with a low survival rate.
Lead Product(s): GLR2007
Therapeutic Area: Oncology Product Name: GLR2007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2021
Details:
GLR2007 is a CDK 4/6 inhibitor that Gan & Lee is developing for the treatment of advanced solid tumors. The Gan & Lee GLR2007 Phase 1 clinical trial is currently enrolling patients to establish the safety, tolerability, and optimal dosing strategy of GLR2007.
Lead Product(s): GLR2007
Therapeutic Area: Oncology Product Name: GLR2007
Highest Development Status: Phase I/ Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2020
Details:
This Phase 1 clinical trial is a multicenter, open- label, study designed to establish the safety, tolerability, and optimal dosing strategy of GLR2007 in patients with advanced solid tumors.
Lead Product(s): GLR2007
Therapeutic Area: Oncology Product Name: GLR2007
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020